Literature DB >> 7809507

Hepatoblastoma.

J T Stocker1.   

Abstract

Hepatoblastoma is the most frequently occurring liver tumor in children, accounting for over 25% pediatric hepatic tumors and nearly 50% of those that are malignant. Histologically, the tumor can be divided into the following six patterns: (1) fetal epithelial; (2) embryonal and fetal epithelial; (3) macrotrabecular; (4) small cell undifferentiated; and (5) mixed epithelial and mesenchymal type with teratoid features or (6) without teratoid features. Immunohistochemical studies display a wide variety of immunostaining with monoclonal antibodies particularly those specific for epithelial-derived components. Tumor cytogenetics show a high incidence of trisomy 20 and trisomy of all or part of chromosome 2. The developing liver displays many features similar to those seen in hepatoblastoma, including uniform hepatocytes and cords two cells thick separated by sinusoids displaying hematopoiesis. Hepatoblastomas display only minimal ductular differentiation, similar to the fetal development of the liver that does not display significant ductular development until well into the second trimester.

Entities:  

Mesh:

Year:  1994        PMID: 7809507

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  9 in total

1.  FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo.

Authors:  Lauren A Gillory; Jerry E Stewart; Michael L Megison; Hugh C Nabers; Elizabeth Mroczek-Musulman; Elizabeth A Beierle
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

2.  Congenital hepatoblastoma in a neonatal alpaca cria.

Authors:  B C Watt; A J Cooley; B J Darien
Journal:  Can Vet J       Date:  2001-11       Impact factor: 1.008

3.  LINC00673 rs11655237 C>T Polymorphism Impacts Hepatoblastoma Susceptibility in Chinese Children.

Authors:  Tianyou Yang; Jiahao Li; Yang Wen; Tianbao Tan; Jiliang Yang; Jing Pan; Chao Hu; Yuxiao Yao; Jiao Zhang; Yijuan Xin; Suhong Li; Huimin Xia; Jing He; Yan Zou
Journal:  Front Genet       Date:  2019-05-24       Impact factor: 4.599

4.  CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells.

Authors:  Yang Yang; Jie Hou; Mingliang Shao; Wei Zhang; Yaling Qi; Shengnan E; Shuqiu Wang; Hongyu Sui; Dexin Meng; Baixin Wang; Mingfu Wang; Yang Han; Yu Cao; Xiaoqing Huang; Yue Li; Pengxia Zhang; Weiqun Wang
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

5.  Identification of differentially expressed genes, lncRNAs and miRNAs which are associated with tumor malignant phenotypes in hepatoblastoma patients.

Authors:  Sida Liu; Fujing Xie; Xiaohong Xiang; Sinan Liu; Shunbin Dong; Kai Qu; Ting Lin
Journal:  Oncotarget       Date:  2017-10-31

6.  NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children.

Authors:  Tianyou Yang; Yang Wen; Jiahao Li; Tianbao Tan; Jiliang Yang; Jing Pan; Chao Hu; Yuxiao Yao; Jiao Zhang; Yijuan Xin; Suhong Li; Huimin Xia; Jing He; Yan Zou
Journal:  Exp Hematol Oncol       Date:  2019-05-09

7.  LncRNA MIR205HG accelerates cell proliferation, migration and invasion in hepatoblastoma through the activation of MAPK signaling pathway and PI3K/AKT signaling pathway.

Authors:  Wei Zhang; Feng Liang; Qingfeng Li; Hong Sun; Fei Li; Zhibo Jiao; Jie Lei
Journal:  Biol Direct       Date:  2022-01-07       Impact factor: 4.540

8.  Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival.

Authors:  Kala Gnanasekaran Kiruthiga; Banumathi Ramakrishna; Soumitra Saha; Sudipta Sen
Journal:  J Gastrointest Oncol       Date:  2018-04

9.  Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mroczek-Musulman; Alicia M Waters; Jennifer M Coleman; Virginia Kelly; James M Markert; G Yancey Gillespie; Gregory K Friedman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.